You are viewing the site in preview mode

Skip to main content

Table 1 Basic characteristics of participants by MASLD and MetALD in NHANES 2017–2018

From: Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders

 

Total (n = 1,862)

Total (n = 1,862)

Non-MASLD (n = 1,027)

MASLD (n = 835)

P-Value

Non-MetALD (n = 1,649)

MetALD (n = 213)

P-Value

NAFLD+, n(%)

6 (0.6%)

835 (100%)

< 0.001

841 (51%)

0 (%)

< 0.001

MAFLD+, n(%)

307 (70%)

818 (98%)

< 0.001

916 (56%)

209 (99%)

< 0.001

MASLD+, n(%)

/

/

 

835 (51%)

0 (%)

< 0.001

MetALD+, n(%)

213 (21%)

0 (%)

< 0.001

/

/

 

Gender, n(%)

  

0.730

  

0.028

Female

515 (50%)

412 (49%)

 

836 (51%)

91 (43%)

 

Male

512 (50%)

423 (51%)

 

813 (49%)

122 (57%)

 

Age (year)

47 (32, 62)

57 (45, 66)

< 0.001

54 (37, 64)

46 (34, 58)

< 0.001

Ethnicity, n(%)

  

0.024

  

< 0.001

Mexican American

142 (14%)

132 (16%)

 

209 (13%)

65 (31%)

 

Non-Hispanic Black

268 (26%)

175 (21%)

 

409 (25%)

34 (16%)

 

Non-Hispanic White

319 (31%)

297 (36%)

 

537 (33%)

79 (37%)

 

Other

298 (29%)

231 (28%)

 

494 (30%)

35 (16%)

 

FIPR

2.15 (1.20, 4.17)

2.64 (1.52, 4.65)

< 0.001

2.49 (1.38, 4.62)

1.85 (1.11, 3.32)

< 0.001

Education, n(%)

  

0.217

  

< 0.001

College or above

589 (57%)

511 (61%)

 

1,005 (61%)

95 (45%)

 

High school or equivalent

254 (25%)

183 (22%)

 

369 (22%)

68 (32%)

 

Less than high school

184 (18%)

140 (17%)

 

274 (17%)

50 (23%)

 

Smoking, n(%)

  

0.006

  

< 0.001

Nonsmoker

564 (55%)

511 (61%)

 

996 (60%)

79 (37%)

 

Smoker

463 (45%)

324 (39%)

 

653 (40%)

134 (63%)

 

Physical Activity

  

0.016

  

0.133

Sedentary

498 (49%)

448 (54%)

 

826 (50%)

120 (56%)

 

Insufficient

131 (13%)

114 (14%)

 

213 (13%)

32 (15%)

 

Moderate

112 (11%)

93 (11%)

 

186 (11%)

19 (8.9%)

 

High

285 (28%)

178 (21%)

 

421 (26%)

42 (20%)

 

BMI (kg/m2)

27 (24, 32)

31 (27, 36)

< 0.001

28 (25, 33)

33 (29, 37)

< 0.001

WC (cm)

94 (84, 105)

106 (97, 117)

< 0.001

98 (88, 111)

108 (99, 119)

< 0.001

FPG (mg/dl)

101 (95, 110)

107 (100, 120)

< 0.001

103 (96, 113)

108 (100, 119)

< 0.001

Hb1Ac (%)

5.50 (5.20, 5.90)

5.90 (5.50, 6.70)

< 0.001

5.60 (5.30, 6.20)

5.70 (5.30, 6.18)

0.633

SBP (mmHg)

121 (111, 134)

127 (116, 138)

< 0.001

123 (112, 137)

125 (115, 136)

0.201

DBP (mmHg)

73 (66, 80)

74 (67, 81)

0.089

73 (66, 79)

76 (69, 85)

< 0.001

TG (mg/dl)

79 (59, 108)

99 (72, 129)

< 0.001

84 (62, 115)

99 (78, 133)

< 0.001

HDL-C (mg/dl)

54 (44, 66)

48 (41, 57)

< 0.001

51 (43, 61)

47 (39, 59)

< 0.001

HOMA-IR

1.99 (1.50, 2.65)

2.48 (1.81, 3.17)

< 0.001

2.12 (1.59, 2.82)

2.40 (1.65, 3.06)

0.045

Hypertension, n(%)

  

< 0.001

  

0.521

No

496 (48%)

241 (29%)

 

657 (40%)

80 (38%)

 

Yes

531 (52%)

594 (71%)

 

992 (60%)

133 (62%)

 

T2DM, n(%)

  

< 0.001

  

0.822

No

807 (79%)

447 (54%)

 

1,112 (67%)

142 (67%)

 

Yes

220 (21%)

388 (46%)

 

537 (33%)

71 (33%)

 

Hyperlipidemia, n(%)

  

< 0.001

  

0.066

No

206 (20%)

64 (8%)

 

248 (15%)

22 (10%)

 

Yes

821 (80%)

771 (92%)

 

1,401 (85%)

191 (90%)

 
  1. NAFLD, non-alcoholic fatty liver disease; MAFLD, Metabolic Associated Fatty Liver Disease; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic alcohol-related liver disease; FIPR, family income-poverty ratio; BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose, SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; T2DM, type 2 diabetes mellitus
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us